Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia
- First Posted Date
- 2020-05-08
- Last Posted Date
- 2020-05-12
- Target Recruit Count
- 60
- Registration Number
- NCT04380376
- Locations
- 🇷🇺
Kirill Zykov, Moscow, Russian Federation
🇷🇺Clinical hospital, Moscow, Russian Federation
Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis
- Conditions
- Interventions
- Drug: CyclophosphamideDrug: JAK InhibitorDrug: FludarabineBiological: Recombinant Granulocyte Colony-Stimulating FactorDrug: MelphalanDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationDrug: TacrolimusRadiation: Total-Body IrradiationProcedure: Computed TomographyProcedure: Magnetic Resonance ImagingProcedure: Bone Marrow BiopsyProcedure: Bone Marrow AspirationProcedure: Biospecimen CollectionProcedure: EchocardiographyProcedure: Multigated Acquisition Scan
- First Posted Date
- 2020-04-30
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT04370301
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Intra-arterial Chemotherapy for Retinoblastoma
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2024-05-14
- Lead Sponsor
- Washington University School of Medicine
- Target Recruit Count
- 5
- Registration Number
- NCT04342572
- Locations
- 🇺🇸
Washington University School of Medicine (Saint Louis Children's Hospital), Saint Louis, Missouri, United States
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 59
- Registration Number
- NCT04339101
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-24
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- Baptist Health South Florida
- Registration Number
- NCT04282174
- Locations
- 🇺🇸
Miami Cancer Institute at Baptist Health, Inc., Miami, Florida, United States
Inhalations of Ultra-low Doses of Melphalan for the Treatment of Non-cystic Fibrosis Bronchiectasis
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2020-02-20
- Target Recruit Count
- 7
- Registration Number
- NCT04278040
- Locations
- 🇷🇺
Kirill Zykov, Moscow, Russian Federation
Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2020-02-11
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 30
- Registration Number
- NCT04264039
- Locations
- 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China
Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2021-06-28
- Lead Sponsor
- Xinqiao Hospital of Chongqing
- Target Recruit Count
- 30
- Registration Number
- NCT04264078
- Locations
- 🇨🇳
Department of Hematology, Xinqiao Hospital, ChongQing, Chongqing, China
Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-12-06
- Target Recruit Count
- 27
- Registration Number
- NCT04232085
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
- Conditions
- Interventions
- First Posted Date
- 2020-01-09
- Last Posted Date
- 2024-05-16
- Lead Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Target Recruit Count
- 800
- Registration Number
- NCT04221035
- Locations
- 🇬🇷
University General Hospital of Thessaloniki "AHEPA", Thessaloniki, Greece
🇬🇷Children's General Hospital "AGHIA SOFIA", Athens, Greece
🇮🇹instituto Giannina Gaslini genova, Genova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.